Pharvaris Announces Proposed Public Offering of Ordinary Shares

Core Viewpoint - Pharvaris N.V. is planning to offer and sell $150 million of ordinary shares to fund research and development, hiring a sales and marketing team in the U.S., and for general corporate purposes [1] Group 1: Offering Details - Pharvaris intends to grant underwriters a 30-day option to purchase an additional $22.5 million of ordinary shares [1] - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1] - The shares are being offered under an effective shelf registration statement filed with the U.S. SEC [3] Group 2: Use of Proceeds - The net proceeds from the offering will primarily fund late-stage clinical programs, sales and marketing team hiring, and working capital [1] Group 3: Company Overview - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases [6] - The company aims to provide injectable-like efficacy and placebo-like tolerability with oral therapies for treating hereditary angioedema (HAE) [6] - Pharvaris is currently conducting pivotal Phase 3 studies for the prevention and on-demand treatment of HAE attacks [6]